Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative
Open Access
- 13 September 2017
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 9 (3), 35
- https://doi.org/10.3390/pharmaceutics9030035
Abstract
Doxorubicin (Dox) is an effective anti-cancer medication with poor oral bioavailability and systemic toxicities. DoxQ was developed by conjugating Dox to the lymphatically absorbed antioxidant quercetin to improve Dox’s bioavailability and tolerability. The purpose of this study was to characterize the pharmacokinetics and safety of Dox after intravenous (IV) and oral (PO) administration of DoxQ or Dox (10 mg/kg) and investigate the intestinal lymphatic delivery of Dox after PO DoxQ administration in male Sprague–Dawley rats. Drug concentrations in serum, urine, and lymph were quantified by HPLC with fluorescence detection. DoxQ intact IV showed a 5-fold increase in the area under the curve (AUC)—18.6 ± 1.98 compared to 3.97 ± 0.71 μg * h/mL after Dox—and a significant reduction in the volume of distribution (Vss): 0.138 ± 0.015 versus 6.35 ± 1.06 L/kg. The fraction excreted unchanged in urine (fe) of IV DoxQ and Dox was ~5% and ~11%, respectively. Cumulative amounts of Dox in the mesenteric lymph fluid after oral DoxQ were twice as high as Dox in a mesenteric lymph duct cannulation rat model. Oral DoxQ increased AUC of Dox by ~1.5-fold compared to after oral Dox. Concentrations of β-N-Acetylglucosaminidase (NAG) but not cardiac troponin (cTnI) were lower after IV DoxQ than Dox. DoxQ altered the pharmacokinetic disposition of Dox, improved its renal safety and oral bioavailability, and is in part transported through intestinal lymphatics.This publication has 62 references indexed in Scilit:
- Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorptionProceedings of the National Academy of Sciences of the United States of America, 2013
- Pharmacometrics of 3-Methoxypterostilbene: A Component of Traditional Chinese Medicinal PlantsEvidence-Based Complementary and Alternative Medicine, 2013
- Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory responseBMC Cardiovascular Disorders, 2012
- Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetinArchives of Pharmacal Research, 2011
- Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancerJournal of Controlled Release, 2010
- Effects of angiotensin II blockade on inflammation‐induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockersBritish Journal of Pharmacology, 2008
- Quercetin appears in the lymph of unanesthetized rats as its phase II metabolites after administered into the stomachFEBS Letters, 2005
- Troponin as a marker of myocardiac damage in drug-induced cardiotoxicityExpert Opinion on Drug Safety, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heartBritish Journal of Pharmacology, 2003